Jorge Castellanos, MD
Cardiovascular Disease · Newport Beach, CANPI 1295969954
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $41,402 of the $62,518 with a category attached, or 66.2%. Surgical Theater. Inc. accounts for 66.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $31,167 and has fallen 97.8% since, to $688 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $353.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Surgical Theater. Inc.$41K
- Edwards Lifesciences$18K
- Abiomed$654
- AbbVie$500
- AstraZeneca$305
- Shockwave Medical, Inc$223
- plus $1K from 14 others
Across 2 payments — averaging $900.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$2K
What the payments were for
- Consulting fees$41,40266%
- Speaking & faculty fees$11,75019%
- Travel & lodging$4,9088%
- Food & beverage$4,3487%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Surgical Theater. Inc. | 28 | $41,378 |
| Edwards Lifesciences | 57 | $18,448 |
| Abiomed | 16 | $654 |
| AbbVie(2 entities) | 19 | $500 |
| AstraZeneca | 16 | $305 |
| Shockwave Medical, Inc | 1 | $223 |
| Amgen | 9 | $164 |
| Medtronic | 4 | $153 |
| Boston Scientific | 5 | $126 |
| Sanofi-aventis U.S. LLC | 1 | $123 |
| Johnson & Johnson | 5 | $122 |
| Merck | 4 | $97 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Chiesi USA, Inc. | 2 | $40 |
| Boehringer Ingelheim | 1 | $28 |
| Cardiovascular Systems Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Novartis | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,518 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 569 | $725,763 |
| EntrestoSacubitril/Valsartan | 179 | $277,692 |
| XareltoRivaroxaban | 93 | $118,645 |
| Repatha SureclickEvolocumab | 104 | $114,280 |
| JardianceEmpagliflozin | 72 | $88,618 |
| Praluent PenAlirocumab | 63 | $62,438 |
| MultaqDronedarone Hcl | 21 | $36,268 |
| Midodrine Hcl | 60 | $12,166 |
| FarxigaDapagliflozin Propanediol | 11 | $9,866 |
| Metoprolol Succinate | 450 | $6,252 |
| Rosuvastatin Calcium | 335 | $5,708 |
| Atorvastatin Calcium | 584 | $5,587 |
| Potassium Chloride | 137 | $5,157 |
| Carvedilol | 441 | $4,998 |
| Ezetimibe | 160 | $4,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $14 | $277,692179 claims |
| Johnson & JohnsonXarelto | $122 | $118,64593 claims |
| Boehringer IngelheimJardiance | $28 | $88,61872 claims |
| Sanofi-aventis U.S. LLCMultaq | $123 | $36,26821 claims |
| AstraZenecaFarxiga | $305 | $9,86611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Newport Beach
- Subbarao MylavarapuNewport Beach$203K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.